3+ day, 4+ hour ago   (301+ words) Sept 11 (Reuters) – AstraZeneca’s breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said ​on Friday, a week after the treatment received U.S. ‌approval. U.S.-listed shares of AstraZeneca…...

4+ day, 4+ hour ago   (109+ words) kfgo.com Novo Nordisk says Wegovy approved in China for liver disease MASH STOCKHOLM, Sept 10 (Reuters) – Denmark’s Novo Nordisk said ​on Thursday its blockbuster weight-loss drug Wegovy had been approved in China ​as ⁠the first ⁠GLP-1 RA class of drugs…...

5+ day, 1+ hour ago   (872+ words) Sept 9 (Reuters) – Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona. A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers reported on…...

5+ day, 18+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

6+ day, 6+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

3+ week, 9+ hour ago   (293+ words) Aug 24 (Reuters) – Eli Lilly has launched its pill, Foundayo, in the UK for weight management and type 2 diabetes, it said on Monday, making Britain ​the first country in Europe where the oral ‌treatment is available. • The pill, known chemically as…...